Trial Profile
A pilot study: Effect of ruxolitinib in myelofibrosis post allogeneic stem cell transplant.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2018
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 23 Jun 2018 New trial record
- 05 Jun 2018 Results assessing effect of uxolitinib (Data cutoff 6/2012 and 6/2017), presented at the 54th Annual Meeting of the American Society of Clinical Oncology